|
Sarilumab Clinical Trials
7 actively recruiting trials across 6 locations
Also known as: Kevzara, Kevzara®, REGN88, REGN88SAR153191, SAR153191
Pipeline
Phase 2: 3Phase 3: 1Phase 1/2: 3
Top Sponsors
- Regeneron Pharmaceuticals5
- University of Nebraska1
- NYU Langone Health1
Indications
- Cancer6
- Endometrial Cancer2
- Ovarian Cancer2
- Advanced/Metastatic Non-Small Cell Lung Cancer1
- Recurrent Primary Peritoneal Cancer1
Birmingham, Alabama2 trials
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
The University of Alabama at Birmingham
Phase 2
Duarte, California1 trial
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
City of Hope Comprehensive Cancer Center
Phase 1/2
Los Angeles, California1 trial
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
The Angeles Clinic at Cedars Sinai
Phase 2
Palo Alto, California1 trial
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Stanford University Medical Center - Blake Wilbur Drive
Phase 1/2
Omaha, Nebraska1 trial
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
University of Nebraska Medical Center
Phase 3
Knoxville, Tennessee1 trial
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
University of Tennessee Medical Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.